Advertisement
Screener

Amphastar Pharmaceuticals, Inc. (AMPH) EBITDA

Amphastar Pharmaceuticals, Inc. (AMPH) EBITDA

  • 2026-06-30: Basis Reported; EBITDA $54.04M; Operating income (m); Depreciation and amortization (m).
  • 2026-03-31: Basis Reported; EBITDA (m); Operating income $13.63M; Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA $39.45M; Operating income (m); Depreciation and amortization (m).
  • 2025-06-30: Basis Reported; EBITDA $56.8M; Operating income (m); Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history
2017-12-31 to 2026-06-30
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported$54.04M(m)(m)(m)29.39%$8.59M*$51.32M*(m)$22.16M(m)$8.20M
2026-03-31Reported(m)$13.63M(m)(m)(m)$9.51M$47.84M(m)$26.74M(m)$3.63M
2025-09-30Reported$39.45M(m)(m)(m)20.56%$5.35M*$52.58M*(m)$22.35M(m)$4.16M
2025-06-30Reported$56.8M(m)(m)(m)32.57%$10.56M*$35.59M*(m)$20.08M(m)$8.30M
2025-03-31Reported(m)$37.29M(m)(m)(m)$10.70M$35.08M(m)$20.10M(m)$5.58M
2024-09-30Reported$70.45M(m)(m)(m)36.84%$13.79M*$59.96M*(m)$21.08M(m)$7.25M
2024-06-30Reported$68.37M(m)(m)(m)37.48%$6.04M*$69.11M*(m)$17.65M(m)$12.29M
2024-03-31Reported$57.67M(m)(m)(m)33.56%$8.79M$55.29M(m)$17.04M(m)$4.13M
2023-12-31Reported$63.64M(m)(m)(m)35.73%(m)(m)(m)(m)(m)(m)
2023-09-30Reported$82.3M(m)(m)(m)45.58%$10.19M*$64.33M*(m)$16.66M(m)$14.03M
2023-06-30Reported$39.96M(m)(m)(m)27.42%$9.05M*$54.92M*(m)$16.84M(m)$6.38M
2023-03-31Reported$36.83M(m)(m)(m)26.30%$9.48M$40.38M(m)$19.82M(m)$6.75M
2022-12-31Reported$41.27M(m)(m)(m)30.57%(m)(m)(m)(m)(m)(m)
2022-09-30Reported$26.65M(m)(m)(m)22.18%$5.62M*$20.38M*(m)$18.51M(m)$6.56M
2022-06-30Reported$27.82M(m)(m)(m)22.53%$5.96M*$2.81M*(m)$22.80M(m)$5.55M
2022-03-31Reported$24.36M(m)(m)(m)20.23%$6.14M$50.77M(m)$16.22M(m)$4.08M
2021-12-31Reported$26.85M(m)(m)(m)22.21%(m)(m)(m)(m)(m)(m)
2021-09-30Reported$27.27M(m)(m)(m)24.31%$7.22M*$2.57M*(m)$10.76M(m)$6.69M
2021-06-30Reported$13.2M(m)(m)(m)12.98%$5.74M*$32.16M*(m)$18.12M(m)$5.59M
2021-03-31Reported$12.79M(m)(m)(m)12.41%$7.62M$22.82M(m)$14.77M(m)$1.16M
2020-12-31Reported$5.38M(m)(m)(m)5.61%(m)(m)(m)(m)(m)(m)
2020-09-30Reported$5.97M(m)(m)(m)7.16%$5.63M*$8.81M*(m)$17.64M(m)$2.29M
2020-06-30Reported-$894,000.00(m)(m)(m)-1.04%$10.89M*$30.09M*(m)$16.15M(m)-$75.00K
2020-03-31Reported$9.53M(m)(m)(m)11.25%$8.01M$1.48M(m)$15.30M(m)$2.28M
2019-12-31Reported$1.82M(m)(m)(m)2.19%(m)(m)(m)(m)(m)(m)
2019-09-30Reported$4.1M(m)(m)(m)5.11%$8.68M*-$12.00M*(m)$18.61M(m)$598.00K
2019-06-30Reported$2.63M(m)(m)(m)3.33%$9.72M*$51.72M*(m)$16.00M(m)$14.17M
2019-03-31Reported-$1.54M(m)(m)(m)-1.93%$14.74M-$3.61M(m)$14.61M(m)-$1.48M
2018-09-30Reported(m)$2.55M(m)(m)(m)$12.63M*$15.78M*(m)$11.34M(m)$958.00K
2018-06-30Reported(m)-$2.94M(m)(m)(m)$12.25M*$4.53M*(m)$15.46M(m)-$1.35M
2018-03-31Reported(m)-$9.78M(m)(m)(m)$12.34M$8.36M(m)$14.03M(m)-$1.75M
2017-09-30Reported(m)-$2.94M(m)(m)(m)$11.41M*$2.47M*(m)$10.07M(m)-$2.21M
2017-06-30Reported(m)$2.19M(m)(m)(m)$6.30M*$4.57M*(m)$10.73M(m)$1.20M
2017-03-31Reported(m)$1.40M(m)(m)(m)$7.27M$22.40M(m)$11.25M(m)$611.00K
2016-09-30Reported(m)$5.80M(m)(m)(m)$6.70M*(m)(m)$9.72M(m)$2.11M
2016-06-30Reported(m)$10.33M(m)(m)(m)$5.40M*(m)(m)$10.59M(m)$2.86M
2016-03-31Reported(m)$4.08M(m)(m)(m)$3.95M(m)(m)$8.61M(m)$1.33M
2015-09-30Reported(m)-$3.75M(m)(m)(m)$3.94M*(m)(m)$11.12M(m)-$1.27M
2015-06-30Reported(m)-$10.26M(m)(m)(m)$2.96M*(m)(m)$10.73M(m)-$3.58M
2015-03-31Reported(m)-$7.26M(m)(m)(m)$3.78M(m)(m)$6.57M(m)-$5.53M
2014-09-30Reported(m)-$7.82M(m)(m)(m)$4.03M*(m)(m)$8.59M(m)-$2.60M
2014-06-30Reported(m)-$1.17M(m)(m)(m)$3.06M*(m)(m)$5.99M(m)-$696.00K
2014-03-31Reported(m)-$1.97M(m)(m)(m)$4.03M(m)(m)$6.21M(m)-$852.00K
2013-09-30Reported(m)$226.00K(m)(m)(m)$4.35M*(m)(m)$9.04M(m)$494.00K
2013-06-30Reported(m)$11.98M(m)(m)(m)(m)(m)(m)$7.79M(m)$4.11M

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported(m)$140.40M(m)(m)(m)$34.88M$156.12M(m)$85.84M(m)$25.53M
2024-12-31Reported(m)$205.42M(m)(m)(m)$41.04M$213.39M(m)$73.91M(m)$29.67M
2023-12-31Reported$222.72M(m)(m)(m)34.56%$38.17M$183.50M(m)$73.74M(m)$31.83M
2022-12-31Reported$120.09M(m)(m)(m)24.07%$24.03M$89.18M(m)$74.77M(m)$23.48M
2021-12-31Reported$80.11M(m)(m)(m)18.30%$27.46M$97.99M(m)$60.93M(m)$20.63M
2020-12-31Reported$19.98M(m)(m)(m)5.71%$33.85M$57.27M(m)$67.23M(m)$3.54M
2019-12-31Reported$7.02M(m)(m)(m)2.18%$41.55M$41.76M(m)$68.85M(m)$13.72M
2018-12-31Reported-$2.57M(m)(m)(m)-0.87%$46.81M$38.19M(m)$57.56M(m)-$3.27M
2017-12-31Reported$5.15M(m)(m)(m)2.14%$35.10M$39.21M(m)$43.50M(m)-$2.40M
2016-12-31Reported(m)$15.38M(m)(m)(m)$21.38M$38.56M(m)$41.52M(m)$4.81M
2015-12-31Reported(m)-$6.90M(m)(m)(m)$16.00M$10.68M(m)$37.27M(m)-$7.58M
2014-12-31Reported(m)-$17.98M(m)(m)(m)$20.50M(m)(m)$28.87M(m)-$7.45M
2013-12-31Reported(m)$17.49M(m)(m)(m)$17.64M(m)(m)$33.02M(m)$5.37M
2012-12-31Reported(m)$25.40M(m)(m)(m)$23.13M(m)(m)$31.16M(m)$7.78M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Seaport Therapeutics, Inc. (SPTX)United States$1.131B
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
MANNKIND CORP (MNKD)United States$1.058B-30.41
Latigo Biotherapeutics, Inc. (LTGO)United States$1.176B
Jaguar Health, Inc. (JAGX)United States$1.184B
Savara Inc (SVRA)United States$1.044B-9.10
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
LB PHARMACEUTICALS INC (LBRX)United States$1.220B-10.87